Junru Liu; Meng Li; Weiying Zheng & Mingzheng Wang
The objective of this study was to observe the clinical efficacy of apatinib (AP) combined with 131I in the treatment of radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) and the prognostic significance of MIP-1α after treatment, and to provide reference and guidance for future treatment and disease assessment of RAIR-DTC. One hundred and six patients with RAIR- DTC admitted to our hospital from January 2019 to October 2020 were selected for the study. All the patients were treated with TC surgery with 131I at our hospital, and 58 of them were subsequently transferred to AP treatment, which was considered as the research group; the other 48 patients were transferred to thyroid stimulating hormone (TSH) suppression treatment, which was considered as the control group. The clinical efficacy of the research group was better than that of the control group (P < 0.05), while no difference was seen in the comparison of the incidence of adverse effects and thyroid function (P > 0.05). After treatment, Tg, TL, maximum diameter of C/B lymph nodes, number of lymph nodes and number of calcified spots were lower in the research group than in the control group (P < 0.05). ROC analysis revealed that the predictive sensitivity of MIP-1α for prognosis of 3-year RAIR-DTC death in the research group of patients was 84.63 % and the specificity was 72.16 %. AP combined with 131I is effective in the treatment of RAIR-DTC and is worth using in the clinical practice. In addition, elevated levels of MIP-1α predicted a poor prognosis for patients with RAIR-DTC.
KEY WORDS: Apatinib; 131I; Radioiodine-refractory differentiated thyroid cancer; MIP-1α; Clinical efficacy.
LIU, J.; LI, M.; ZHENG, W. & WANG, M. Clinical effect observation of apatinib combined with 131I for radioiodine-refractory differentiated thyroid cancer and prognostic significance analysis of macrophage inflammatory protein-1α after treatment: A cell regulation study. Int. J. Morphol., 42(2):409-415, 2024.
